Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

K Reich, KA Papp, A Blauvelt, SK Tyring, R Sinclair… - The Lancet, 2017 - thelancet.com
Background Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting
interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis …
被引用次数：540 相关文章

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

K Reich, KA Papp, A Blauvelt, SK Tyring, R Sinclair… - The Lancet, 2017 - thelancet.com
Background Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting
interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis …

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

K Reich, KA Papp, A Blauvelt, SK Tyring, R Sinclair… - The Lancet, 2017 - Elsevier
Background Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting
interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis …

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

K Reich, KA Papp, A Blauvelt, SK Tyring… - The …, 2017 - research.uni-luebeck.de
Background Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting
interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis …

[引用][C] Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 …

K Reich, KA Papp, A Blauvelt, SK Tyring, R Sinclair… - The Lancet, 2017 - cir.nii.ac.jp
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and
reSURFACE 2): results from two randomised controlled, phase 3 trials | CiNii Research CiNii …

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.

K Reich, KA Papp, A Blauvelt, SK Tyring… - Lancet (London …, 2017 - europepmc.org
Background Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting
interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis …

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

K Reich, KA Papp, A Blauvelt… - Lancet (London …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting
interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis …
[PDF] sinclairdermatology.com.au

[PDF][PDF] Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 …

K Reich, KA Papp, A Blauvelt, SK Tyring… - …, 2017 - sinclairdermatology.com.au
Background Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting
interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis …

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

K Reich, KA Papp, A Blauvelt, SK Tyring… - The …, 2017 - research.uni-luebeck.de
Background Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting
interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis …